“showed a trend”

PIK3CA -mutant PDX models showed a trend toward an improved response to alpelisib as well (one-tailed p = 0.07).

Although only 7% of patients (43/659) received the cisplatin plus 5-fluorouracil regimen because of the covid-19 pandemic and late enrolment of western populations, this regimen also showed a trend for survival benefit (hazard ratio for overall survival 0.31, 95% confidence interval 0.08 to 1.20, P=0.07).

More specifically, the prognosis of stage I and II right- and left-sided CRCs was similar (HR = 0.69 [0.35–1.35], p = 0.28 and HR = 0.85 [0.59–1.23], p = 0.40, respectively), stage III right-sided tumors showed a trend towards poorer OS (HR = 1.34 [0.98–1.85], p = 0.07), whereas stage IV right-sided CRCs had a significantly worse outcome (HR = 1.55 [1.13–2.12], p = 0.005).

In contrast, the difference between the two control groups’ STs only showed a trend, t (52) = -3.38, p = .07.

Levene’s test for group differences in variance in CT in the Group MFG Cluster showed a trend towards a group difference (Levene’s statistic = 2.7, p = 0.07).

The presence of DDR gene alterations, most commonly identified in ERCC2 , showed a trend for better bladder or metastatic recurrence-free survival (HR 0.47, p = 0.070); this finding is in line with studies on neoadjuvant chemotherapy for MIBC [ 48 , 49 ] and systemic chemotherapy for advanced urothelial carcinoma [ 50 ], showing significantly better clinical outcomes for tumors with DDR gene alterations.

The authors also showed a trend toward an increased pCR rate with higher doses (15%, 23%, and 33%, respectively) (p = 0.07).

Interhemispheric functional connectivity For interhemispheric connectivity between non-dominant M1 and sensorimotor ROIs in the contralateral, dominant hemisphere, rmANOVA analyses with the between-subject factor ‘group’ (uCP, TD) and the within-subjects factor ‘interhemispheric M1-connectivity’ showed a trend toward a ‘group*connection’ interaction (F (3, 82) = 2.45, p = 0.07, Wilks’ Lambda = 0.92), indicating a different pattern between ROI pairs in each group (Table 1 , Fig. 1c ).

Similarly, patients presenting the highest angiogenin levels presented a normal MRC score at 6 months ( p = 0.043; Figure 4D ) and functional outcomes assessed by the Rankin scale also showed a trend toward better improvement at 1 month ( p = 0.07; Figure 4E ), showing the association between high angiogenin levels and better neurological improvements.

Methotrexate use showed a trend towards a lower IMT value ( p = 0.07).

Remarkably, the high dose of 1.5 mg was ineffective, but the low dose of 0.5 mg showed a trend towards a 50–61% decrease in the number of new enhancing lesions as compared with placebo ( p = 0.07).

Even though the present study was not designed to test muscle function, we showed a trend towards the increase in whole body muscle quality when RT was added to CR ( p = 0.07), suggesting that in humans, RT improves muscle function regardless of muscle mass changes during CR.

They also showed a trend towards higher plasma enzyme activity compared to non-N215S (0.25 vs. 0.17 nmol/ml/hr, p = 0.07).

There was a significant improvement from baseline to post-treatment scores for all outcome measures in both groups; however, no significant interactions between treatment and visit were detected ( Table 3 ), meaning that the change from baseline was similar in the two treatment groups, although FMA-UE showed a trend for interaction (p = 0.07) with bigger changes in the M-TOTgroup.

Although not statistically different, the CE group showed a trend (p < 0.07) for higher NAFLD activity score than the C group.

SHR‐lean rats showed a trend towards reduced radial fractional shortening of the left atrium in the annular ( P =0.07) and posterior ( P =0.10) segment, although these changes did not achieve statistical significance.

Similarly, RFD in the reactive force test was reduced after the concentric protocol and showed a trend for a reduction after the eccentric test ( p = 0.07; Figure 3 ).

During the go/no-go task, there was a treatment × trial × group interaction, although this finding only showed a trend towards statistical significance ( F 26 = 3.38, P = 0.07).

The results showed a trend of lower incidence of GVHD in G-BM comparing to that in unstimulated BM group (II–IV aGVHD, 12.2% vs 26.78%, P = 0.070; overall cGVHD 22.3% vs 37.5%, P = 0.120, respectively).

Of note, despite the small sample size, a PN in melanoma patients showed a trend toward increased odds of finding metastatic disease on biopsy, with an OR of 9.09 (95% CI, 0.83 to 99.73; P = .07).

To analyse if these associations were driven by the STI clinic participants, we ran the logistic regression by site of recruitment ( Table 6 ), finding that having a part-time job (OR 2.5, 95% CI 1.12–5.78) and trimming the pubic hair (OR 2.1, 95% CI 1.06–4.01) remained risk factors for colonisation among the STI clinic participants, having more than 6 heterosexual sexual partners in the previous 6 months only showed a trend (OR 3.9, p = 0.07) We then looked for risk factors with respect to specific body site colonisation.

Although by days 3–7 the 0.9% saline and PPL groups were very similar, the 0.9% saline replacement group only showed a trend toward a difference compared to the morphine group ( P = 0.07).

Moreover, SLeA overexpression showed a trend association with decreased OS in GC ( p = 0.07).

RA reservoir strain showed a trend towards increase from baseline (50.2 ± 12.1%) to the first altitude examination (53.8 ± 11.0%, p = 0.07) secondary to a significant increase of RA contraction strain (19.2 ± 6.4 vs. 25.4 ± 9.6%, p < 0.001).

Typicality showed a trend towards an increase versus Experiment 1 [F(1,218) = 3.48, p < 0.07], and was significantly increased relative to Experiment 2a [F(1,39) = 17.22, p < 0.0002, partial ω 2 = 0.29].